MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

NUC-7738 is under clinical development by NuCana and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for B-Cell Non-Hodgkin Lymphoma have a 36% phase ...

GD2-CART01 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Medulloblastoma.

SCO-267 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetes, nonalcoholic fatty liver disease and obesity. It acts by targeting GPR40. It is administered through ...

Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Polycystic Ovarian Syndrome.

Plasmodium Immunotherapy is under clinical development by CAS-Lamvac Biotech and currently in Phase II for Thyroid Cancer.

LAE-005 (FAZ-053) is under development for the treatment of advanced solid tumors including chordoma, alveolar soft part sarcoma, triple negative breast cancer. It is administered through intravenous ...

Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Oropharyngeal Cancer.

TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).

ORYN-1001 is under clinical development by Oryn Therapeutics and currently in Phase I for Rheumatoid Arthritis.

Trilaciclib is under clinical development by Pharmacosmos and currently in Phase III for Triple-Negative Breast Cancer (TNBC).